

Heart protection study

Submission date 06/04/2000	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 06/04/2000	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 30/07/2012	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Rory Collins

Contact details

Clinical Trial Service Unit
Radcliffe Infirmary
Oxford
United Kingdom
OX2 6HE

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

G9123430

Study information

Scientific Title

Study objectives

1. Providing unequivocal evidence about the effects of cholesterol-lowering drug therapy with simvastatin on total mortality among high-risk patients
2. Demonstrating reliably the effects on coronary heart disease (CHD) within several subgroups where there is still uncertainty (e.g. women, elderly, below-average cholesterol, hypertensive)
3. Providing reliable information about effects on non-cardiac mortality and morbidity (i.e. cancer, trauma, etc.), on vascular surgery and other hospitalisations and any major side-effects
4. Assessing effects of vitamin supplementation on CHD

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised placebo controlled factorial design trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Coronary heart disease (CHD)

Interventions

Patients were randomised in a 2 x 2 factorial design to receive:

1. 40 mg simvastatin daily or matching placebo tablets
2. Antioxidant vitamins (vitamins E, C and beta-carotene) or matching placebo capsules

Treatment duration was for five years.

Intervention Type

Supplement

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Simvastatin, vitamins E and C, beta-carotene

Primary outcome measure

1. Total mortality and cause-specific mortality for statin comparison
2. Total CHD and fatal CHD for vitamin comparison
3. Major vascular events and total CHD for subgroups

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/1994

Completion date

01/10/2001

Eligibility**Key inclusion criteria**

1. Patients at high risk of CHD (e.g., because of history of vascular disease or diabetes)
2. Without clear indication for or contra-indication to statin
3. Male and female adults
4. Non-fasting blood total cholesterol concentrations of at least 3.5 mmol/L (135 mg/dL)

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

20,000

Key exclusion criteria

1. The patient's doctor considered statin therapy to be clearly indicated or contra-indicated
2. A past history of: stroke, myocardial infarction or angina hospitalisation within the previous six months
3. Chronic liver disease or evidence of abnormal liver function
4. Severe renal disease or evidence of substantially impaired renal function
5. Inflammatory muscle disease or evidence of muscle problems
6. Concurrent treatment with cyclosporin, fibrates or high-dose niacin
7. Child-bearing potential
8. Severe heart failure
9. Life-threatening conditions other than vascular disease or diabetes (including any cancer except non-melanoma skin cancer)
10. Any other condition that might limit long-term compliance

Date of first enrolment

01/01/1994

Date of final enrolment

01/10/2001

Locations

Countries of recruitment

England

United Kingdom

Study participating centre**Clinical Trial Service Unit**

Oxford

United Kingdom

OX2 6HE

Sponsor information

Organisation

Medical Research Council (MRC) (UK)

Sponsor details

20 Park Crescent

London

United Kingdom

W1B 1AL

+44 (0)20 7636 5422

clinical.trial@headoffice.mrc.ac.uk

Sponsor type

Research council

Website

<http://www.mrc.ac.uk>

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council (MRC) (UK)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	16/03/2005		Yes	No
Results article	results	23/01/2007		Yes	No
Results article	results	31/03/2009		Yes	No
Results article	genetic variant results	01/02/2011		Yes	No
Results article	results	05/02/2011		Yes	No
Results article	results	17/05/2011		Yes	No
Results article	results	22/05/2012		Yes	No
Results article	sub-study results on cholesterol and risk of vascular events	22/05/2012		Yes	No